CD8A and sarcoma: In a chemically induced sarcoma mouse model, vaccination with long neoantigen peptides capable of activating both CD4+ and CD8+ T cell responses induced tumor rejection comparable to that achieved with immune checkpoint inhibitor therapy (24).